TAS-116 is primarily utilized in the field of oncology as a selective inhibitor of heat shock protein 90 (HSP90). Its application is focused on targeting cancer cells by disrupting the function of HSP90, which is crucial for the stability and activity of numerous oncogenic proteins. By inhibiting HSP90, TAS-116 promotes the degradation of these cancer-promoting proteins, thereby inhibiting tumor growth and survival. It is particularly investigated in the treatment of various cancers, including gastrointestinal stromal tumors (GISTs) and other malignancies driven by HSP90-dependent pathways. Clinical studies are ongoing to evaluate its efficacy, safety, and potential as a therapeutic agent in cancer treatment regimens.